Loading...
Publication
O papel dos agonistas do recetor do GLP-1 no tratamento da obesidade em diabéticos e não diabéticos
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| Documento em Acesso Embargado até dia 23-02-2028. Tente solicitar cópia ao autor carregando no ficheiro | 1.13 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Introdução: A obesidade é um problema de saúde crescente, sendo um dos principais fatores de risco para doenças não transmissíveis. Um dos tratamentos recentes que se destaca são os agonistas do recetor do GLP-1 (GLP-1R). O GLP-1, uma incretina produzida pelo intestino após a ingestão de alimentos, estimula a secreção de insulina dependente de glicose, reduzindo a glicemia, além de modular o apetite e a ingestão de energia. Os agonistas do GLP-1R, amplamente utilizados no controlo da diabetes tipo 2, mostraram reduzir o peso corporal de forma significativa. Objetivos: Esta revisão bibliográfica tem como objetivo analisar o papel dos agonistas do GLP-R1 no tratamento da obesidade em doentes diabéticos e não diabéticos. Métodos: Este estudo incluiu um total de 9 artigos, obtidos através de uma pesquisa com as palavras-chave “(obesity[MeSH Major Topic]) AND (Glucagon-Like Peptide 1[MeSH Major Topic]) AND (Humans) NOT (Diabetes Mellitus),” e “(obesity[MeSH Major Topic])) AND (Glucagon-Like Peptide 1[MeSH Major Topic]) AND (Humans) AND (Diabetes Mellitus)”, na plataforma PubMed e tendo em conta os critérios de inclusão e exclusão estabelecidos. Resultados: Em ensaios clínicos os agonistas do GLP-1R semaglutido e liraglutido têm demonstrado eficácia na redução de peso e melhoria dos parâmetros metabólicos. O semaglutido, em doses semanais de 2,4 mg, resultou nos participantes não diabéticos em perdas de peso de até 17,4%, superando o placebo. O liraglutido é eficaz, mas com uma perda de peso mais modesta, alcançando até 8,0% na dose diária de 3,0 mg. Nos pacientes diabéticos, o semaglutido demonstrou maior perda de peso (até 9,6%) em comparação ao liraglutido (até 6,0%). Discussão: Embora ambos os fármacos apresentem benefícios metabólicos, o semaglutido destaca-se pela sua eficácia e conveniência da administração semanal, devendo a escolha entre os dois tratamentos considerar as necessidades e características individuais de cada paciente. Os efeitos adversos mais proeminentes foram os gastrointestinais, nomeadamente náuseas, vómitos, obstipação e diarreia. Conclusão: Os agonistas do GLP-1R constituem uma abordagem terapêutica eficaz e promissora para a obesidade, justificando a sua crescente relevância no panorama clínico atual.
Introduction: Obesity is a growing health problem and one of the main risk factors for non-communicable diseases. One of the most prominent recent treatments is GLP-1 receptor agonists (GLP-1R). GLP-1, an incretin produced by the gut after food intake, stimulates glucose-dependent insulin secretion, reducing blood glucose and modulating appetite and energy intake. GLP-1R agonists, widely used to control type 2 diabetes, have been shown to reduce body weight significantly. Objectives: This literature review aims to analyze the role of GLP-R1 agonists in the treatment of obesity in diabetic and non-diabetic patients. Methods: This study included a total of 9 articles, obtained through a search using the keywords “(obesity[MeSH Major Topic]) AND (Glucagon-Like Peptide 1[MeSH Major Topic]) AND (Humans) NOT (Diabetes Mellitus),” and “(obesity[MeSH Major Topic])) AND (Glucagon-Like Peptide 1[MeSH Major Topic]) AND (Humans) AND (Diabetes Mellitus)”, on the PubMed platform and taking into account the established inclusion and exclusion criteria. Results: In clinical trials, the GLP-1R agonists semaglutide and liraglutide have shown efficacy in reducing weight and improving metabolic parameters. Semaglutide, in weekly doses of 2,4 mg, resulted in weight losses of up to 17,4% in non-diabetic participants, outperforming placebo. Liraglutide is effective, but with a more modest weight loss, reaching up to 8,0% at a daily dose of 3,0 mg. In diabetic patients, semaglutide showed greater weight loss (up to 9,6%) than liraglutide (up to 6,0%). Discussion: Although both drugs have metabolic benefits, semaglutide stands out for its efficacy and convenience in weekly administration. The choice between the two treatments should consider each patient's individual needs and characteristics. The most prominent adverse effects were gastrointestinal, namely nausea, vomiting, constipation, and diarrhea. Conclusion: GLP-1R agonists are an effective and promising therapeutic approach for obesity, justifying their growing relevance in today's clinical landscape.
Introduction: Obesity is a growing health problem and one of the main risk factors for non-communicable diseases. One of the most prominent recent treatments is GLP-1 receptor agonists (GLP-1R). GLP-1, an incretin produced by the gut after food intake, stimulates glucose-dependent insulin secretion, reducing blood glucose and modulating appetite and energy intake. GLP-1R agonists, widely used to control type 2 diabetes, have been shown to reduce body weight significantly. Objectives: This literature review aims to analyze the role of GLP-R1 agonists in the treatment of obesity in diabetic and non-diabetic patients. Methods: This study included a total of 9 articles, obtained through a search using the keywords “(obesity[MeSH Major Topic]) AND (Glucagon-Like Peptide 1[MeSH Major Topic]) AND (Humans) NOT (Diabetes Mellitus),” and “(obesity[MeSH Major Topic])) AND (Glucagon-Like Peptide 1[MeSH Major Topic]) AND (Humans) AND (Diabetes Mellitus)”, on the PubMed platform and taking into account the established inclusion and exclusion criteria. Results: In clinical trials, the GLP-1R agonists semaglutide and liraglutide have shown efficacy in reducing weight and improving metabolic parameters. Semaglutide, in weekly doses of 2,4 mg, resulted in weight losses of up to 17,4% in non-diabetic participants, outperforming placebo. Liraglutide is effective, but with a more modest weight loss, reaching up to 8,0% at a daily dose of 3,0 mg. In diabetic patients, semaglutide showed greater weight loss (up to 9,6%) than liraglutide (up to 6,0%). Discussion: Although both drugs have metabolic benefits, semaglutide stands out for its efficacy and convenience in weekly administration. The choice between the two treatments should consider each patient's individual needs and characteristics. The most prominent adverse effects were gastrointestinal, namely nausea, vomiting, constipation, and diarrhea. Conclusion: GLP-1R agonists are an effective and promising therapeutic approach for obesity, justifying their growing relevance in today's clinical landscape.
Description
Keywords
Semaglutido Liraglutido Perda de peso Obesidade Diabetes Mellitus Weight loss Obesity